Despegar.com (NYSE:DESP) Azioni

Despegar.com

Despegar.com Corp is an online travel company in Latin America. Its product offering includes airline tickets, packages, hotels, and other travel-related products, which enables consumers to find, compare, plan and purchase travel products easily through its marketplace. The company provides a technology platform for managing the distribution of products and access to users to the network of travel suppliers. It operates through two segments: Air, which consists of the sale of airline tickets; and Packages, Hotels, and Other Travel Products, which consists of travel packages, as well as sales of hotel rooms, car rentals, bus tickets, cruise tickets, travel insurance and destination services. Its geographical segments are Argentina, Brazil, Uruguay, Mexico, and other countries.

Despegar.com Corp

On April 15, 2025, Satellogic Inc. (the "Company") entered into a&nbsp;securities purchase agreement&nbsp;(the "Purchase Agreement") with the purchaser party thereto, pursuant to which the Company agreed to issue and sell in a registered direct offering (the "Offering"), 6,451,612 shares (the "Shares") of the Company's Class A common stock, par value $0.0001 per share (the "Class A Common Stock"), at an offering price of $3.10 per share. The gross proceeds to the Company from the Offering are approximately $20.0 million, before deducting the Placement Agent's (as defined below) fees and estimated offering expenses payable by the Company. Closing of the Offering is expected to occur on April 16, 2025, subject to satisfaction of customary closing conditions.

News

Offerings

SATL

Satellogic Entered Into $20M Securities Purchase Agreement; To Issue And Sell 6,451,612 Shares At $3.10 Per Share

WIIM

Mirion Technologies shares are trading lower after Citigroup cut its price target on the stock from $20 to $17.

At a time when buzzwords and high-frequency trading tend to get all the attention, Argent Capital Management has taken a lower-key — but more strategic — approach. The St. Louis active asset manager has launched <a href="https://www.benzinga.com/etfs">two new ETFs</a>: the Argent Large Cap ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABIG#NASDAQ">ABIG</a>) and the Argent Focused Small Cap ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALIL#NASDAQ">ALIL</a>). These complement the firm&#8217;s already existing Mid Cap ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMID#NASDAQ">AMID</a>), providing a complete array of U.S. equity exposure that adheres to a rather old-fashioned policy: invest in good companies and let them compound.
Also Read:<a href="https://www.benzinga.com/25/04/44800249/wisdomtrees-fund-just-got-a-makeover-and-its-built-for-market-chaos"> WisdomTree Fund Gets A Makeover That&#8217;s Built For Market Chaos</a>
Argent&#8217;s strategy focuses on the idea it calls &#8220;enduring businesses&#8221; — companies with steadily increasing cash flows, sound capital allocation habits and a lasting competitive advantage. &#8220;We think of it as the economic version of a well-built house that stands strong in all weather. We look closely at how a company reinvests its profits, manages debt, and maintains its edge over competitors. Even as markets rapidly evolve, these fundamental strengths rarely go out of style,&#8221; ABIG portfolio manager Jed Ellerbroek, Jr., told Benzinga.
These are not big, index-hugging funds. Each is constructed with conviction: about 30 to 35 names in ABIG and 35 to 45 in ALIL. That focused method reflects Argent&#8217;s view that meaningful long-term outperformance results from extensive fundamental research and allowing great businesses to do what they do best—compound cash flows over time.
&#8220;Good capital allocation is like planting trees today, knowing they&#8217;ll provide shade in the future. It takes patience,&#8221; Ellerbroek said. &#8220;We seek companies that consistently reinvest cash wisely to fuel long-term growth. When volatility hits, our conviction in these disciplined firms allows us to look beyond short-term and hold positions confidently for years, compounding returns along the way.&#8221;
In today&#8217;s market, that conviction causes them to be overweight in sectors like consumer discretionary and industrials within ABIG. Amazon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) is the fund&#8217;s largest holding and a key driver of that discretionary tilt. Argent also prefers stocks like Copart (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CPRT#NASDAQ">CPRT</a>), Booz Allen Hamilton (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAH#NYSE">BAH</a>) and Waste Connections (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WCN#NYSE">WCN</a>) for their consistent cash flows and resilient business models. At the same time, they&#8217;re underweight in consumer staples, which they consider less attractive compared to some industrials.
Also Read: <a href="https://www.benzinga.com/25/04/44799456/chip-shock-3-hot-semiconductor-etfs-to-watch-as-trumps-tariff-bomb-ticks">Chip Shock: 3 Hot Semiconductor ETFs To Watch As Trump&#8217;s Tariff Bomb Ticks</a>
In ALIL — the small-cap cousin — Argent is making the most of financials and housing-related consumer discretionary names. Ellerbroek cites strong long-term growth opportunities and favorable valuations in both areas. Conversely, the team is cautious about a few companies that don&#8217;t have their quality-first approach. 
&#8220;For ALIL, our small cap strategy, we&#8217;re overweight consumer discretionary, especially housing-related names, given their attractive long-term growth potential,&#8221; he said. &#8220;We're also overweight in financials, thanks to compelling secular trends and reasonable valuations. Meanwhile, we're cautious on healthcare, largely due to our aversion to unprofitable biotech businesses.&#8221;
That research-led approach is particularly important in the small-cap space, where analyst coverage can be thin and market narratives can shift quickly. According to Ellerbroek, the firm conducts small-cap due diligence more like private equity investors than public market traders. &#8220;We're asking ourselves, &#8216;Would we want our own families to own this business?&#8217; This mindset ensures we invest only in businesses we deeply understand and believe can compound value over time.&#8221;
<a href="https://www.prweb.com/releases/argent-capital-management-adds-two-etfs-to-its-growing-lineup-of-investment-solutions-302423047.html">Argent&#8217;s </a>commitment to quality applies to risk management as well. Volatility isn&#8217;t risk; owning lousy businesses is. &#8220;Owning exceptionally high-quality companies, we can confidently look beyond short-term fluctuations, knowing these businesses are built to adapt and thrive over the long term,&#8221; Ellerbroek said.
With three concentrated ETFs now accessible for large-, mid- and small-cap stocks, Argent views a natural opportunity for advisers to create an all-weather core equity portfolio with their funds. ABIG represents a solid large-cap anchor, AMID focuses on mid-cap growth opportunities, and ALIL provides access to emerging opportunities in the small-cap universe.
In a market filled with passive approaches and moment-in-the-sun thematic ETFs, Argent is counting on something that has remained consistent: fundamental research, patience and the compounding power of quality businesses.
As a parting thought, summarizing Argent's investment approach, Ellerbroek told Benzinga, &#8220;We invest in a select group of great businesses that steadily compound cash flow and have lasting competitive advantages &#8211; because in investing, short-term thinking rarely wins; patience usually does.&#8221;
Next Up: 
<ul>
<li><a href="https://www.benzinga.com/25/04/44799117/us-iran-talks-fuel-oil-rally-here-are-5-energy-etfs-in-the-radar">US-Iran Talks Fuel Oil Rally: Here Are 3 Energy ETFs In The Radar</a></li>
</ul>
Photo: Shutterstock

New ETFs

Exclusives

Interview

ETFs

ABIG

ALIL

AMID

AMZN

CPRT

Exclusive: Argent's New ETFs Are Not Chasing AI Or Meme Stocks, Here's What They're Buying Instead

Barclays analyst Dan Levy maintains Ford Motor (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/F#NYSE">F</a>) with a Equal-Weight and lowers the price target from $10 to $8.

Price Target

Analyst Ratings

Barclays Maintains Equal-Weight on Ford Motor, Lowers Price Target to $8

Mizuho analyst Siti Panigrahi maintains Workday (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WDAY#NASDAQ">WDAY</a>) with a Outperform and lowers the price target from $320 to $275.

WDAY

Mizuho Maintains Outperform on Workday, Lowers Price Target to $275

General

LCID

Lucid Announces 2026 Lucid Gravity

SANTA CLARA, Calif., April 15, 2025 (GLOBE NEWSWIRE) -- NVIDIA today announced the NVIDIA GeForce RTX&#x2122; 5060 family of GPUs, including two graphics cards that deliver neural rendering and NVIDIA Blackwell architecture innovations for every gamer — starting at just $299.
The GeForce RTX 5060 Ti and RTX 5060 graphics cards feature <a href="https://www.nvidia.com/en-us/geforce/technologies/dlss/">NVIDIA DLSS 4</a>, full ray tracing, neural rendering and <a href="https://www.nvidia.com/en-us/geforce/technologies/reflex/">NVIDIA Reflex</a> technologies for exceptional performance and image quality.
"The RTX 5060 family offers gamers next-generation performance and AI-enhanced visuals starting at $299," said Matt Wuebbling, vice president of GeForce marketing at NVIDIA. "Powered by the advanced NVIDIA Blackwell architecture and featuring DLSS 4 technology in over 100 games, this new class of GPUs elevates gaming with stunning visuals, high frame rates and quick responsiveness."

NVDA

NVIDIA Unveils GeForce RTX 5060 GPUs Starting at $299

Management

First American Financial Appoints Mark E. Seaton To CEO; Succeeds Ken DeGiorgio; Matt F. Wajner Appointed To CFO And Chairman

<ul>
<li>Program aims to achieve the best possible treatment outcomes — longer lives with fewer side-effects — without excess financial strain.</li>
<li>Collegial provider engagement model brings together education, technology and incentives to encourage top-quality regimens.</li>
<li>One low-value regimen costs about 70 times more than a clinically equivalent alternative.</li>
</ul>
WASHINGTON, April 15, 2025 /PRNewswire/ -- When treating patients with cancer, oncologists typically can choose from multiple FDA-approved regimens, or combinations of drugs.
While tools such as Evolent's clinical pathways can help them find high-value options, providers have not had similar resources to flag regimens on the opposite side of the spectrum. These other regimens may be associated with lower survival, more severe side effects, or extremely high cost without additional clinical benefits.
Today, in the Journal of Clinical Pathways, Evolent oncology experts <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4405248-1&amp;h=1442647278&amp;u=https%3A%2F%2Fwww.hmpgloballearningnetwork.com%2Fsite%2Fjcp%2Ffield%2Fturning-pathways-their-head-deimplementation-low-value-treatment-regimens&amp;a=reported">reported</a> on their efforts to identify these "low-value regimens" and then decrease their use by more than 20%, following a multifaceted provider education and engagement campaign with a national payer partner.
"For oncologists, selecting between available treatment options can be a close call, but there are certain regimens that miss by a wide margin," said Evolent CMO Emeritus and Senior Advisor Dr. Andrew Hertler. "While low-value options represent a tiny percentage of cancer drugs ordered, avoiding them can have an outsize impact on both the quality and affordability of care for patients. Given that medications are the largest component of spending on cancer care — about 60 percent for Medicare populations — we need to ensure we are investing in therapies that offer patients the greatest promise for longer, better lives."
The low-value regimen program spans therapies across 10 common cancer types, representing about 1 percent of all requests that Evolent receives. Each regimen was identified by Evolent clinical experts after a thorough examination of the medical literature, as well as real-world outcomes. They were then reviewed and approved by the company's Oncology Scientific Advisory Board, which consists of leading community and academic oncologists from across the U.S.
The Evolent team found dramatic differences between high- and low-value regimens. For example, one low-value lung cancer regimen is about 70 times more expensive — or $40,000 more per quarter — than a preferred alternative. Yet the evidence to date does not support that it offers better clinical outcomes.
In early 2023, Evolent and a national health plan partner embarked on a multifaceted campaign to voluntarily reduce use of these regimens in multiple markets. Outreach included provider awareness efforts, such as in-person and virtual forums where Evolent oncology pharmacists reviewed the evidence with practice-based clinicians. White papers and videos also supported the education effort.
Leveraging technology, Evolent also flagged low-value regimens as non-preferred in its clinical decision support system. If a provider still requested one of these therapies, it triggered outreach from an Evolent clinical reviewer, who sought to understand the particulars of the case, go over the evidence, and explore higher-value options the provider could voluntarily switch to.
Evolent also administered pay-for-performance programs that incentivize providers for using preferred regimens while de-incentivizing low-value options. And the use of low-value regimens was a key metric on specialist scorecards that Evolent disseminates to oncology practices and referring providers.
From February through May 2024, the use of low-value regimens decreased by 20.1%, compared to the same four-month period in 2023. That change was driven in large part by shifts in ordering habits — provider requests for low-value regimens dropped by 15.5 percent.&nbsp;
"The low-value regimen program showcases the power of our provider engagement model to drive change," said Evolent Chief Medical Officer Dr. Von Nguyen. "Increasing providers' awareness of low-value regimens is a critical piece of the puzzle, requiring multiple touchpoints and real relationships built on trust. Still, awareness alone is not enough. We leverage technology, performance reporting and the right incentive structures to keep these issues top of mind and sustain improvement over the long term."
Evolent's low-value regimen program is now active with health plans across the U.S.

Evolent Announces Program Achieves 20% Reduction In Use Of Low-Value Oncology Regimens. Program Active With Health Plans Across The U.S.

PSTV

Plus Therapeutics shares are trading higher after the company announced the new data highlighting the safety and benefits of REYOBIQ.

Mizuho analyst Siti Panigrahi maintains UiPath (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PATH#NYSE">PATH</a>) with a Neutral and lowers the price target from $12 to $11.

PATH

Mizuho Maintains Neutral on UiPath, Lowers Price Target to $11

In the preceding three months, 5 analysts have released ratings for Tenet Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/THC#NYSE">THC</a>), presenting a wide array of perspectives from bullish to bearish.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $161.0, a high estimate of $177.00, and a low estimate of $137.00. This current average represents a 7.11% decrease from the previous average price target of $173.33. 
<img src="https://www.benzinga.com/files/images/story/2025/1744722121_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
The standing of Tenet Healthcare among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;--------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Michael Ha &#x7C;Baird &#x7C;Lowers &#x7C;Neutral &#x7C; $137.00&#x7C;$153.00 &#x7C; 
&#x7C;Jason Cassorla &#x7C;Guggenheim &#x7C;Announces &#x7C;Buy &#x7C; $165.00&#x7C;- &#x7C; 
&#x7C;Craig Hettenbach &#x7C;Morgan Stanley &#x7C;Announces &#x7C;Overweight &#x7C; $165.00&#x7C;- &#x7C; 
&#x7C;Sarah James &#x7C;Cantor Fitzgerald &#x7C;Maintains &#x7C;Overweight &#x7C; $177.00&#x7C;$177.00 &#x7C; 
&#x7C;Andrew Mok &#x7C;Barclays &#x7C;Lowers &#x7C;Overweight &#x7C; $161.00&#x7C;$190.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Tenet Healthcare. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Tenet Healthcare compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of Tenet Healthcare's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Tenet Healthcare's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/THC/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Tenet Healthcare analyst ratings.</a>
<h2>Unveiling the Story Behind Tenet Healthcare</h2>
Tenet Healthcare is a Dallas-based healthcare services organization. It operates acute and specialty hospitals (47 as of December 2024) and over 500 ambulatory surgery centers and other outpatient facilities across the US, primarily in the South. Through its Conifer segment, Tenet also provides revenue cycle management solutions.
<h3>Tenet Healthcare's Economic Impact: An Analysis</h3>
Market Capitalization Highlights: Above the industry average, the company's market capitalization signifies a significant scale, indicating strong confidence and market prominence.
Negative Revenue Trend: Examining Tenet Healthcare's financials over 3M reveals challenges. As of 31 December, 2024, the company experienced a decline of approximately -5.71% in revenue growth, reflecting a decrease in top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Tenet Healthcare's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 6.27% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 7.95%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Tenet Healthcare's ROA excels beyond industry benchmarks, reaching 1.09%. This signifies efficient management of assets and strong financial health.
Debt Management: Tenet Healthcare's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 3.16.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Deep Dive Into Tenet Healthcare Stock: Analyst Perspectives (5 Ratings)

Contracts

TTEK

Tetra Tech Wins $8M Contract To Provide Engineering Design And Technical Services For Wastewater Treatment Modernization Program

During the last three months, 16 analysts shared their evaluations of Neurocrine Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NBIX#NASDAQ">NBIX</a>), revealing diverse outlooks from bullish to bearish.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">10</td>
<td align="right">5</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">6</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $165.44, a high estimate of $185.00, and a low estimate of $137.00. Observing a downward trend, the current average is 3.59% lower than the prior average price target of $171.60. 
<img src="https://www.benzinga.com/files/images/story/2025/1744722112_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Neurocrine Biosciences. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;--------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Ami Fadia &#x7C;Needham &#x7C;Announces &#x7C;Buy &#x7C; $138.00&#x7C;- &#x7C; 
&#x7C;Brian Abrahams &#x7C;RBC Capital &#x7C;Lowers &#x7C;Outperform &#x7C; $137.00&#x7C;$138.00 &#x7C; 
&#x7C;Ashwani Verma &#x7C;UBS &#x7C;Lowers &#x7C;Buy &#x7C; $137.00&#x7C;$154.00 &#x7C; 
&#x7C;Anupam Rama &#x7C;JP Morgan &#x7C;Raises &#x7C;Overweight &#x7C; $184.00&#x7C;$183.00 &#x7C; 
&#x7C;Jeffrey Hung &#x7C;Morgan Stanley &#x7C;Lowers &#x7C;Overweight &#x7C; $150.00&#x7C;$185.00 &#x7C; 
&#x7C;Andrew Fein &#x7C;HC Wainwright &amp; Co. &#x7C;Maintains &#x7C;Buy &#x7C; $185.00&#x7C;$185.00 &#x7C; 
&#x7C;Andrew Fein &#x7C;HC Wainwright &amp; Co. &#x7C;Maintains &#x7C;Buy &#x7C; $185.00&#x7C;$185.00 &#x7C; 
&#x7C;Yatin Suneja &#x7C;Guggenheim &#x7C;Lowers &#x7C;Buy &#x7C; $163.00&#x7C;$165.00 &#x7C; 
&#x7C;Andrew Fein &#x7C;HC Wainwright &amp; Co. &#x7C;Lowers &#x7C;Buy &#x7C; $185.00&#x7C;$190.00 &#x7C; 
&#x7C;Brian Abrahams &#x7C;RBC Capital &#x7C;Lowers &#x7C;Sector Perform &#x7C; $148.00&#x7C;$154.00 &#x7C; 
&#x7C;Laura Chico &#x7C;Wedbush &#x7C;Lowers &#x7C;Outperform &#x7C; $147.00&#x7C;$157.00 &#x7C; 
&#x7C;Sumant Kulkarni &#x7C;Canaccord Genuity &#x7C;Lowers &#x7C;Buy &#x7C; $163.00&#x7C;$172.00 &#x7C; 
&#x7C;Andrew Fein &#x7C;HC Wainwright &amp; Co. &#x7C;Lowers &#x7C;Buy &#x7C; $185.00&#x7C;$190.00 &#x7C; 
&#x7C;Tazeen Ahmad &#x7C;B of A Securities &#x7C;Lowers &#x7C;Buy &#x7C; $179.00&#x7C;$184.00 &#x7C; 
&#x7C;Jeffrey Hung &#x7C;Morgan Stanley &#x7C;Raises &#x7C;Overweight &#x7C; $185.00&#x7C;$170.00 &#x7C; 
&#x7C;Ashwani Verma &#x7C;UBS &#x7C;Raises &#x7C;Buy &#x7C; $176.00&#x7C;$162.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Neurocrine Biosciences. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Neurocrine Biosciences compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Neurocrine Biosciences's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
For valuable insights into Neurocrine Biosciences's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/NBIX/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Neurocrine Biosciences analyst ratings.</a>
<h2>About Neurocrine Biosciences</h2>
Neurocrine Biosciences Inc engages in the discovery, development, and commercialization of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.
<h3>Understanding the Numbers: Neurocrine Biosciences's Finances</h3>
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
Revenue Growth: Over the 3M period, Neurocrine Biosciences showcased positive performance, achieving a revenue growth rate of 21.84% as of 31 December, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: Neurocrine Biosciences's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of 16.43%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Neurocrine Biosciences's ROE excels beyond industry benchmarks, reaching 3.88%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Neurocrine Biosciences's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 2.84%, the company showcases efficient use of assets and strong financial health.
Debt Management: Neurocrine Biosciences's debt-to-equity ratio is below the industry average. With a ratio of 0.18, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>What Are Analyst Ratings?</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

NBIX

What 16 Analyst Ratings Have To Say About Neurocrine Biosciences

Providing a diverse range of perspectives from bullish to bearish, 9 analysts have published ratings on TE Connectivity (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEL#NYSE">TEL</a>) in the last three months.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">2</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated TE Connectivity and provided 12-month price targets. The average target is $159.44, accompanied by a high estimate of $170.00 and a low estimate of $142.00. A negative shift in sentiment is evident as analysts have decreased the average price target by 4.21%. 
<img src="https://www.benzinga.com/files/images/story/2025/1744722104_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
The analysis of recent analyst actions sheds light on the perception of TE Connectivity by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;--------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Luke Junk &#x7C;Baird &#x7C;Lowers &#x7C;Outperform &#x7C; $147.00&#x7C;$150.00 &#x7C; 
&#x7C;Asiya Merchant &#x7C;Citigroup &#x7C;Lowers &#x7C;Neutral &#x7C; $142.00&#x7C;$165.00 &#x7C; 
&#x7C;Mark Delaney &#x7C;Goldman Sachs &#x7C;Lowers &#x7C;Buy &#x7C; $170.00&#x7C;$190.00 &#x7C; 
&#x7C;Chris Snyder &#x7C;UBS &#x7C;Lowers &#x7C;Buy &#x7C; $155.00&#x7C;$188.00 &#x7C; 
&#x7C;William Stein &#x7C;Truist Securities &#x7C;Lowers &#x7C;Hold &#x7C; $163.00&#x7C;$165.00 &#x7C; 
&#x7C;Colin Langan &#x7C;Wells Fargo &#x7C;Raises &#x7C;Equal-Weight &#x7C; $155.00&#x7C;$151.00 &#x7C; 
&#x7C;Wamsi Mohan &#x7C;B of A Securities &#x7C;Raises &#x7C;Buy &#x7C; $170.00&#x7C;$167.00 &#x7C; 
&#x7C;Luke Junk &#x7C;Baird &#x7C;Raises &#x7C;Outperform &#x7C; $168.00&#x7C;$162.00 &#x7C; 
&#x7C;Asiya Merchant &#x7C;Citigroup &#x7C;Raises &#x7C;Neutral &#x7C; $165.00&#x7C;$160.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to TE Connectivity. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of TE Connectivity compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of TE Connectivity's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of TE Connectivity's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/TEL/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on TE Connectivity analyst ratings.</a>
<h2>Delving into TE Connectivity's Background</h2>
TE Connectivity is the largest electrical connector supplier in the world, supplying interconnect and sensor solutions to the transportation, industrial, and communications markets. With operations in 150 countries and over 500,000 stock-keeping units, TE has a broad portfolio that forms the electrical architecture of its end customers' cutting-edge innovations.
<h3>TE Connectivity: A Financial Overview</h3>
Market Capitalization: Exceeding industry standards, the company's market capitalization places it above industry average in size relative to peers. This emphasizes its significant scale and robust market position.
Revenue Growth: TE Connectivity's revenue growth over a period of 3M has been noteworthy. As of 31 December, 2024, the company achieved a revenue growth rate of approximately 0.13%. This indicates a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Information Technology sector.
Net Margin: TE Connectivity's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 13.76%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 4.26%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): TE Connectivity's ROA excels beyond industry benchmarks, reaching 2.33%. This signifies efficient management of assets and strong financial health.
Debt Management: TE Connectivity's debt-to-equity ratio is below the industry average at 0.34, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>What Are Analyst Ratings?</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

9 Analysts Assess TE Connectivity: What You Need To Know

Mizuho analyst Siti Panigrahi maintains Twilio (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TWLO#NYSE">TWLO</a>) with a Outperform and lowers the price target from $165 to $125.

TWLO

Mizuho Maintains Outperform on Twilio, Lowers Price Target to $125

Across the recent three months, 14 analysts have shared their insights on NEXTracker (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXT#NASDAQ">NXT</a>), expressing a variety of opinions spanning from bullish to bearish.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">5</td>
<td align="right">8</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">5</td>
<td align="right">5</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $56.57, a high estimate of $66.00, and a low estimate of $48.00. This current average has increased by 8.0% from the previous average price target of $52.38. 
<img src="https://www.benzinga.com/files/images/story/2025/1744722095_0.png" alt="price target chart" />
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
The perception of NEXTracker by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;---------------------&#x7C;-------------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Ben Kallo &#x7C;Baird &#x7C;Lowers &#x7C;Outperform &#x7C; $48.00&#x7C;$59.00 &#x7C; 
&#x7C;Christine Cho &#x7C;Barclays &#x7C;Lowers &#x7C;Overweight &#x7C; $58.00&#x7C;$60.00 &#x7C; 
&#x7C;Christopher Dendrinos&#x7C;RBC Capital &#x7C;Announces &#x7C;Outperform &#x7C; $55.00&#x7C;- &#x7C; 
&#x7C;Julien Dumoulin-Smith&#x7C;Jefferies &#x7C;Raises &#x7C;Buy &#x7C; $56.00&#x7C;$46.00 &#x7C; 
&#x7C;Ameet Thakkar &#x7C;BMO Capital &#x7C;Raises &#x7C;Market Perform &#x7C; $50.00&#x7C;$48.00 &#x7C; 
&#x7C;Brian Lee &#x7C;Goldman Sachs &#x7C;Raises &#x7C;Buy &#x7C; $61.00&#x7C;$54.00 &#x7C; 
&#x7C;Joseph Osha &#x7C;Guggenheim &#x7C;Raises &#x7C;Buy &#x7C; $62.00&#x7C;$50.00 &#x7C; 
&#x7C;Biju Perincheril &#x7C;Susquehanna &#x7C;Raises &#x7C;Positive &#x7C; $54.00&#x7C;$50.00 &#x7C; 
&#x7C;Jon Windham &#x7C;UBS &#x7C;Raises &#x7C;Buy &#x7C; $66.00&#x7C;$60.00 &#x7C; 
&#x7C;Kashy Harrison &#x7C;Piper Sandler &#x7C;Raises &#x7C;Overweight &#x7C; $50.00&#x7C;$47.00 &#x7C; 
&#x7C;Jordan Levy &#x7C;Truist Securities &#x7C;Raises &#x7C;Buy &#x7C; $56.00&#x7C;$54.00 &#x7C; 
&#x7C;Mark Strouse &#x7C;JP Morgan &#x7C;Raises &#x7C;Overweight &#x7C; $61.00&#x7C;$58.00 &#x7C; 
&#x7C;Gus Richard &#x7C;Northland Capital Markets&#x7C;Raises &#x7C;Outperform &#x7C; $55.00&#x7C;$48.00 &#x7C; 
&#x7C;Christine Cho &#x7C;Barclays &#x7C;Raises &#x7C;Overweight &#x7C; $60.00&#x7C;$47.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to NEXTracker. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of NEXTracker compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of NEXTracker's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/NXT/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on NEXTracker analyst ratings.</a>
<h2>Unveiling the Story Behind NEXTracker</h2>
Nextracker (and its subsidiaries) is a leading provider of intelligent, integrated solar tracker and software solutions used in utility-scale and distributed generation solar projects around the world. Nextracker's products enable solar panels in utility-scale power plants to follow the sun's movement across the sky and optimize plant performance. Nextracker has operations in the United States, Mexico, Spain and other countries in Europe, India, Australia, the Middle East, Africa, and Brazil.
<h3>Unraveling the Financial Story of NEXTracker</h3>
Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Challenges: NEXTracker's revenue growth over 3M faced difficulties. As of 31 December, 2024, the company experienced a decline of approximately -4.37%. This indicates a decrease in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Industrials sector.
Net Margin: NEXTracker's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 16.97%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): NEXTracker's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 8.63% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 4.01%, the company showcases effective utilization of assets.
Debt Management: NEXTracker's debt-to-equity ratio is below the industry average at 0.1, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>Analyst Ratings: What Are They?</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Beyond The Numbers: 14 Analysts Discuss NEXTracker Stock

14 analysts have shared their evaluations of Sempra (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SRE#NYSE">SRE</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">7</td>
<td align="right">6</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">4</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $80.57, along with a high estimate of $95.00 and a low estimate of $70.00. A decline of 13.37% from the prior average price target is evident in the current average. 
<img src="https://www.benzinga.com/files/images/story/2025/1744722086_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
A clear picture of Sempra's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;---------------------&#x7C;--------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Julien Dumoulin-Smith&#x7C;Jefferies &#x7C;Lowers &#x7C;Hold &#x7C; $75.00&#x7C;$77.00 &#x7C; 
&#x7C;Ryan Levine &#x7C;Citigroup &#x7C;Lowers &#x7C;Neutral &#x7C; $70.00&#x7C;$93.00 &#x7C; 
&#x7C;Sarah Akers &#x7C;Wells Fargo &#x7C;Lowers &#x7C;Overweight &#x7C; $85.00&#x7C;$88.00 &#x7C; 
&#x7C;David Arcaro &#x7C;Morgan Stanley &#x7C;Raises &#x7C;Overweight &#x7C; $86.00&#x7C;$85.00 &#x7C; 
&#x7C;James Thalacker &#x7C;BMO Capital &#x7C;Lowers &#x7C;Outperform &#x7C; $78.00&#x7C;$92.00 &#x7C; 
&#x7C;Julien Dumoulin-Smith&#x7C;Jefferies &#x7C;Lowers &#x7C;Hold &#x7C; $77.00&#x7C;$96.00 &#x7C; 
&#x7C;Nicholas Campanella &#x7C;Barclays &#x7C;Lowers &#x7C;Equal-Weight &#x7C; $72.00&#x7C;$95.00 &#x7C; 
&#x7C;Carly Davenport &#x7C;Goldman Sachs &#x7C;Lowers &#x7C;Neutral &#x7C; $76.00&#x7C;$99.00 &#x7C; 
&#x7C;Anthony Crowdell &#x7C;Mizuho &#x7C;Lowers &#x7C;Outperform &#x7C; $76.00&#x7C;$92.00 &#x7C; 
&#x7C;Shahriar Pourreza &#x7C;Guggenheim &#x7C;Lowers &#x7C;Buy &#x7C; $87.00&#x7C;$95.00 &#x7C; 
&#x7C;David Arcaro &#x7C;Morgan Stanley &#x7C;Lowers &#x7C;Overweight &#x7C; $85.00&#x7C;$100.00 &#x7C; 
&#x7C;Daniel Ford &#x7C;UBS &#x7C;Lowers &#x7C;Neutral &#x7C; $78.00&#x7C;$95.00 &#x7C; 
&#x7C;Sarah Akers &#x7C;Wells Fargo &#x7C;Lowers &#x7C;Overweight &#x7C; $88.00&#x7C;$96.00 &#x7C; 
&#x7C;Eric Beaumont &#x7C;Barclays &#x7C;Lowers &#x7C;Overweight &#x7C; $95.00&#x7C;$99.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Sempra. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Sempra compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Sempra's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Sempra's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/SRE/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Sempra analyst ratings.</a>
<h2>Discovering Sempra: A Closer Look</h2>
Sempra Energy serves one of the largest utility customer bases in the United States. It distributes natural gas and electricity in Southern California and owns 80% of Oncor, a transmission and distribution business in Texas. SoCalGas and San Diego Gas &amp; Electric distribute gas to more than 20 million customers, while Oncor serves more than 10 million Texas customers. Sempra Infrastructure partners, of which Sempra holds a controlling ownership, owns and operates liquefied natural gas facilities in North America and infrastructure in Mexico.
<h3>Key Indicators: Sempra's Financial Health</h3>
Market Capitalization: Boasting an elevated market capitalization, the company surpasses industry averages. This signals substantial size and strong market recognition.
Revenue Growth: Over the 3M period, Sempra showcased positive performance, achieving a revenue growth rate of 7.65% as of 31 December, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Utilities sector.
Net Margin: Sempra's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 17.7% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Sempra's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of 2.25%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 0.7%, the company showcases effective utilization of assets.
Debt Management: Sempra's debt-to-equity ratio is below the industry average at 1.18, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>How Are Analyst Ratings Determined?</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Expectations For Sempra's Future

Providing a diverse range of perspectives from bullish to bearish, 4 analysts have published ratings on The Interpublic Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IPG#NYSE">IPG</a>) in the last three months.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $34.25, along with a high estimate of $39.00 and a low estimate of $27.00. Surpassing the previous average price target of $31.00, the current average has increased by 10.48%.
<img src="https://www.benzinga.com/files/images/story/2025/1744722078_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive The Interpublic Group. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;--------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Jason Bazinet &#x7C;Citigroup &#x7C;Announces &#x7C;Buy &#x7C; $35.00&#x7C;- &#x7C; 
&#x7C;Adam Berlin &#x7C;UBS &#x7C;Lowers &#x7C;Neutral &#x7C; $27.00&#x7C;$29.00 &#x7C; 
&#x7C;David Karnovsky &#x7C;JP Morgan &#x7C;Raises &#x7C;Overweight &#x7C; $39.00&#x7C;$32.00 &#x7C; 
&#x7C;Julien Roch &#x7C;Barclays &#x7C;Raises &#x7C;Overweight &#x7C; $36.00&#x7C;$32.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to The Interpublic Group. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of The Interpublic Group compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for The Interpublic Group's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Capture valuable insights into The Interpublic Group's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/IPG/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on The Interpublic Group analyst ratings.</a>
<h2>Get to Know The Interpublic Group Better</h2>
Interpublic Group is among the world's largest advertising holding companies based on annual revenue. It provides traditional advertising services along with digital and other services such as public relations through various acquisitions. IPG has made these services available in over 100 countries. The company generates about 65% of revenue in the US and 17% in the UK and Europe. IPG agreed to merge with Omnicom in December 2024, pending regulatory approval.
<h3>A Deep Dive into The Interpublic Group's Financials</h3>
Market Capitalization Analysis: With an elevated market capitalization, the company stands out above industry averages, showcasing substantial size and market acknowledgment.
Revenue Growth: The Interpublic Group's revenue growth over a period of 3M has faced challenges. As of 31 December, 2024, the company experienced a revenue decline of approximately -5.5%. This indicates a decrease in the company's top-line earnings. When compared to others in the Communication Services sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: The Interpublic Group's net margin is impressive, surpassing industry averages. With a net margin of 12.06%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): The Interpublic Group's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 9.16% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): The Interpublic Group's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 1.95%, the company showcases efficient use of assets and strong financial health.
Debt Management: The Interpublic Group's debt-to-equity ratio is below the industry average. With a ratio of 1.12, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

A Glimpse Into The Expert Outlook On The Interpublic Group Through 4 Analysts

Biotech

LYEL

Lyell Immunopharma Receives Regenerative Medicine Advanced Therapy Designation For LYL314 In Treatment Of Relapsed And/Or Refractory Large B-Cell Lymphoma

Press Releases

Nubank and Despegar Announce Integration of Nupay on Despegar's Travel Platform

Despegar Licenses its AI Technology to Karisma Hotels & Resorts

Despegar.com to Announce Third Quarter 2024 Financial Results on November 14, 2024

Despegar.com Announces 3Q24 Financial Results

L Catterton Latin America Makes Strategic Investment in WeVets

Despegar.com Enters Into Merger Agreement to Be Acquired by Prosus for $19.50 Per Share in Cash

Prosus to Acquire Latin America's Leading Online Travel Agency, Despegar, for US$1.7bn

Shareholder Alert: Ademi LLP investigates whether Despegar.com, Corp. is obtaining a Fair Price for its Public Shareholders

$HAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Despegar.com, Corp. - DESP

Despegar and HBX Group Enter Into a Strategic Partnership

DESP

Airbnb

Atour Lifestyle Holdings Limited - American Depositary Shares

Atour Lifestyle Holdings

Booking Holdings

Choice Hotels International, Inc. Common Stock

Choice Hotels Intl

Expedia Group

Global Business Travel Group, Inc. Class A Common Stock

Global Business Travel

GreenTree Hospitality Group Ltd. American depositary shares, each representing one Class A ordinary share

GreenTree Hospitality Gr

Hyatt Hotels Corporation Class A Common Stock

Hyatt Hotels

Hilton Grand Vacations

Hilton Worldwide Holdings Inc. Common Stock

Hilton Worldwide Holdings

H World Group Limited - American Depositary Shares

H World Group

Intercontinental Hotels Group American Depositary Shares (Each representing one Ordinary Share)

Comments

Despegar.com

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO